Institutional investor Baker Bros purchased over $600 million worth of the stock, a significant vote of confidence from a successful long-term holder.

Listed as one of the biotech/pharma companies the speaker holds positive views on and/or has positions in.

The speaker is bullish on the company, stating that he 'likes' it.

Mentioned briefly as a stock that the speaker likes, suggesting a bullish view.